fda glp-1 warning letters november 2025 issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's September crackdown on misleading FDA Issues Warning Letters to
Description
Finally, SGLT1 is expressed in human heart capillaries and whether this plays a role in cardiac protection remains to be determined (238)
Within months, the conversation shifted from clinical promise to commercial success
The relationship between GLP-1 receptor agonists and eye problems is complex and requires careful interpretation of available evidence
For example, a patient who does not have insurance coverage may be better suited for phentermine, which is relatively inexpensive
Scand J Gastroenterol 2018;53:1429-32.ArticlePubMed 45
